GlassScriptPhysician profile
Jill Logothetis
NPI 1558749796
$3,250.77
in general payments reported to CMS, 2019-2025
17 companies · $831 in 2025
The $831 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $704 · 2023: $456 · 2024: $576 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $778.69 | 2021-2025 | Dyanavel Xr |
| Corium, LLC | $643.98 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $484.67 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $284.59 | 2021-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $262.97 | 2022-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $181.22 | 2021-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $165.68 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $153.95 | 2021-2022 | |
| Adlon Therapeutics L.P. | $66.05 | 2021 | |
| Pfizer INC. | $60.69 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $35.53 | 2022-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Cranial Technologies, INC | $27.33 | 2025 | Doc Band |
| Aimmune Therapeutics, INC. | $24.99 | 2021 | |
| Sanofi Pasteur INC. | $22.91 | 2023 | |
| Sobi, INC | $19.65 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $19.44 | 2025 | Neurostar Tms Therapy System |
| Astrazeneca Pharmaceuticals LP | $18.43 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Logothetis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.